Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARMC10_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ARMC10_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ARMC10_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ARMC10_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARMC10_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
GO:0072331111 | Esophagus | ESCC | signal transduction by p53 class mediator | 121/8552 | 163/18723 | 9.61e-14 | 4.69e-12 | 121 |
GO:2001243111 | Esophagus | ESCC | negative regulation of intrinsic apoptotic signaling pathway | 78/8552 | 98/18723 | 5.50e-12 | 2.10e-10 | 78 |
GO:1901796111 | Esophagus | ESCC | regulation of signal transduction by p53 class mediator | 70/8552 | 93/18723 | 5.69e-09 | 1.18e-07 | 70 |
GO:0072332111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway by p53 class mediator | 59/8552 | 76/18723 | 1.22e-08 | 2.42e-07 | 59 |
GO:1902253110 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 23/8552 | 29/18723 | 2.25e-04 | 1.40e-03 | 23 |
GO:19017975 | Esophagus | ESCC | negative regulation of signal transduction by p53 class mediator | 22/8552 | 31/18723 | 3.90e-03 | 1.58e-02 | 22 |
GO:19022544 | Esophagus | ESCC | negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 16/8552 | 21/18723 | 4.47e-03 | 1.76e-02 | 16 |
GO:200123312 | Liver | Cirrhotic | regulation of apoptotic signaling pathway | 163/4634 | 356/18723 | 2.62e-18 | 4.43e-16 | 163 |
GO:009719312 | Liver | Cirrhotic | intrinsic apoptotic signaling pathway | 130/4634 | 288/18723 | 2.69e-14 | 2.45e-12 | 130 |
GO:20012427 | Liver | Cirrhotic | regulation of intrinsic apoptotic signaling pathway | 82/4634 | 164/18723 | 2.35e-12 | 1.71e-10 | 82 |
GO:20012347 | Liver | Cirrhotic | negative regulation of apoptotic signaling pathway | 102/4634 | 224/18723 | 8.40e-12 | 5.60e-10 | 102 |
GO:20012437 | Liver | Cirrhotic | negative regulation of intrinsic apoptotic signaling pathway | 47/4634 | 98/18723 | 5.26e-07 | 1.17e-05 | 47 |
GO:007233112 | Liver | Cirrhotic | signal transduction by p53 class mediator | 69/4634 | 163/18723 | 5.97e-07 | 1.30e-05 | 69 |
GO:00723326 | Liver | Cirrhotic | intrinsic apoptotic signaling pathway by p53 class mediator | 38/4634 | 76/18723 | 1.75e-06 | 3.32e-05 | 38 |
GO:190179612 | Liver | Cirrhotic | regulation of signal transduction by p53 class mediator | 37/4634 | 93/18723 | 9.58e-04 | 6.78e-03 | 37 |
GO:19022535 | Liver | Cirrhotic | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 14/4634 | 29/18723 | 5.09e-03 | 2.62e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARMC10 | SNV | Missense_Mutation | novel | c.376N>A | p.Ala126Thr | p.A126T | Q8N2F6 | protein_coding | deleterious(0.03) | probably_damaging(0.981) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARMC10 | SNV | Missense_Mutation | novel | c.713N>C | p.Val238Ala | p.V238A | Q8N2F6 | protein_coding | tolerated(0.05) | possibly_damaging(0.77) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARMC10 | SNV | Missense_Mutation | novel | c.376G>A | p.Ala126Thr | p.A126T | Q8N2F6 | protein_coding | deleterious(0.03) | probably_damaging(0.981) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARMC10 | SNV | Missense_Mutation | novel | c.766C>A | p.Leu256Ile | p.L256I | Q8N2F6 | protein_coding | deleterious(0.02) | possibly_damaging(0.872) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARMC10 | SNV | Missense_Mutation | novel | c.533N>G | p.Tyr178Cys | p.Y178C | Q8N2F6 | protein_coding | deleterious(0.02) | probably_damaging(0.959) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARMC10 | SNV | Missense_Mutation | | c.899N>G | p.Gln300Arg | p.Q300R | Q8N2F6 | protein_coding | tolerated(0.21) | benign(0.022) | TCGA-DD-A1EA-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ARMC10 | insertion | Frame_Shift_Ins | novel | c.969_970insG | p.Leu324ValfsTer3 | p.L324Vfs*3 | Q8N2F6 | protein_coding | | | TCGA-DD-A1EE-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
ARMC10 | insertion | Frame_Shift_Ins | novel | c.971_972insTCCTGAGC | p.Leu324PhefsTer12 | p.L324Ffs*12 | Q8N2F6 | protein_coding | | | TCGA-DD-A1EE-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
ARMC10 | SNV | Missense_Mutation | novel | c.950N>A | p.Cys317Tyr | p.C317Y | Q8N2F6 | protein_coding | tolerated(0.06) | benign(0.317) | TCGA-05-4432-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
ARMC10 | SNV | Missense_Mutation | novel | c.823N>A | p.Glu275Lys | p.E275K | Q8N2F6 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-33-6738-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | gemcitabine | SD |